Foghorn Therapeutics Inc. Common Stock (FHTX) Stock Price

FHTXStock

$6.00+19.76%52W

Market Cap$356.31M

P/E—

PEG Ratio—

Div yield—

Beta2.95

FHTX Share Price Chart

Favorite Metrics

Price vs S&P 500 (26W)-6.11%

Price vs S&P 500 (4W)28.61%

VGM Score58.40

Book Value / Share (Quarterly)$0.00

P/TBV (Annual)1643.45x

Indicated Dividend (Annual)$0.00

Revenue Growth (3Y)17.14%

Cash Flow / Share (Quarterly)$-1.44

Price vs S&P 500 (YTD)-1.71%

Net Profit Margin (TTM)-175.78%

EPS (TTM)$-0.98

10-Day Avg Trading Volume0.44M

EPS Excl Extra (TTM)$-0.98

Revenue Growth (5Y)135.14%

EPS (Annual)$-1.18

ROI (Annual)-108880.00%

Net Profit Margin (5Y Avg)-1830.74%

Cash / Share (Quarterly)$2.85

Revenue Growth QoQ (YoY)112.68%

ROA (Last FY)-37.50%

Revenue Growth TTM (YoY)51.98%

EBITD / Share (TTM)$-1.06

Operating Margin (TTM)-198.04%

Cash Flow / Share (Annual)$-1.52

P/B Ratio3854.11x

P/B Ratio (Quarterly)2666.96x

Net Income / Employee (Annual)$-700,800

EV / Revenue (TTM)8.64x

Net Interest Coverage (TTM)-52.05x

ROA (TTM)-31.17%

EPS Incl Extra (Annual)$-1.18

Current Ratio (Annual)2.73x

Quick Ratio (Quarterly)3.31x

3-Month Avg Trading Volume0.26M

52-Week Price Return19.76%

Revenue / Employee (TTM)$346,600

Tangible BV / Share (Quarterly)$-1.36

P/S Ratio (Annual)12.47x

Asset Turnover (Annual)0.16x

52-Week High$7.61

Operating Margin (5Y Avg)-1876.78%

EPS Excl Extra (Annual)$-1.18

CapEx CAGR (5Y)-68.53%

26-Week Price Return5.82%

Quick Ratio (Annual)2.68x

13-Week Price Return40.52%

Total Debt / Equity (Annual)0.00x

Current Ratio (Quarterly)3.36x

Enterprise Value$317.33M

Revenue / Share Growth (5Y)111.13%

Asset Turnover (TTM)0.18x

Revenue / Employee (Annual)$291,600

Pretax Margin (Annual)-240.33%

Cash / Share (Annual)$2.80

3-Month Return Std Dev81.49%

Net Income / Employee (TTM)$-609,200

ROE (Last FY)-108880.00%

Net Interest Coverage (Annual)-51.77x

EPS Basic Excl Extra (Annual)$-1.18

Total Debt / Equity (Quarterly)0.00x

EPS Incl Extra (TTM)$-0.98

Receivables Turnover (Annual)0.13x

ROI (TTM)-301.61%

P/S Ratio (TTM)10.49x

Pretax Margin (5Y Avg)-1828.27%

Revenue / Share (Annual)$0.49

Tangible BV / Share (Annual)$0.00

Price vs S&P 500 (52W)1.20%

Year-to-Date Return11.11%

5-Day Price Return-12.66%

EPS Normalized (Annual)$-1.18

ROA (5Y Avg)-29.76%

Net Profit Margin (Annual)-240.33%

Month-to-Date Return32.45%

Cash Flow / Share (TTM)$-2.38

EBITD / Share (Annual)$-1.32

Operating Margin (Annual)-279.49%

LT Debt / Equity (Annual)0.00x

LT Debt / Equity (Quarterly)0.00x

EPS Basic Excl Extra (TTM)$-0.98

P/B Ratio (Annual)2666.96x

Pretax Margin (TTM)-175.78%

Book Value / Share (Annual)$0.00

Price vs S&P 500 (13W)38.56%

Beta2.95x

P/FCF (Annual)2.00x

Revenue / Share (TTM)$0.52

ROE (TTM)-301.61%

52-Week Low$3.27

vGradeD

gGradeA

mGradeB

vgmGradeC

FHTX Earnings Surprise History

Quarter	Report date	EPS estimate	EPS actual	Surprise
Q2 2026	Aug 6, 2026	-$0.23	-$0.10	+57.06%(+$0.13)
Q1 2026	May 7, 2026	-$0.31	-$0.29	+7.20%(+$0.02)
Q4 2025	Mar 11, 2026	-$0.26	-$0.37	-42.36%(-$0.11)
Q3 2025	Nov 5, 2025	-$0.30	-$0.25	+16.67%(+$0.05)
Q2 2025	Aug 5, 2025	-$0.32	-$0.28	+12.04%(+$0.04)

FHTX Analyst Recommendations

May 2026

Jun 2026

Jul 2026

Aug 2026

4.38

Industry Peers — Pharmaceuticals(570)

Symbol	Value Score	Growth Score	Momentum Score	Price
FHTXFoghorn Therapeutics Inc. Common Stock	D	A	B	$6.00
LLYEli Lilly & Co.	D	B	C	$1174.61
JNJJohnson & Johnson	D	C	B	$268.04
ABBVABBVIE INC.	D	C	B	$255.48
MRKMerck & Co., Inc.	D	C	B	$148.35
NVSNovartis AG	C	C	C	$153.81
AZNAstraZeneca PLC	C	B	C	$162.70
NVONovo-Nordisk A/S	B	C	C	$45.61
ABTAbbott Laboratories	C	C	C	$112.47
PFEPfizer Inc.	C	D	B	$27.96
VRTXVertex Pharmaceuticals Inc	D	C	B	$541.69
BMYBristol-Myers Squibb Co.	B	B	B	$66.58
SNYSanofi American Depositary Shares (Each representing one-half of one ordinary share)	B	C	C	$44.82
GSKGSK plc American Depositary Shares (Each representing two Ordinary Shares)	B	C	C	$50.82
REGNRegeneron Pharmaceuticals Inc	C	C	B	$794.19
TAKTakeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)	C	C	B	$18.03
TEVATeva Pharmaceutical Industries Limited American Depositary Shares	C	C	C	$36.44
ONCBeOne Medicines Ltd. American Depositary Shares	D	B	B	$366.73
RPRXRoyalty Pharma plc Class A Ordinary Shares	D	D	B	$60.85
ZTSZOETIS INC.	C	C	D	$77.34
ALNYAlnylam Pharmaceuticals, Inc.	D	A	D	$237.10
INSMInsmed, Inc.	F	A	C	$118.54
ROIVRoivant Sciences Ltd. Common Shares	D	F	B	$34.71
UTHRUnited Therapeutics Corp	C	C	B	$515.46
GMABGenmab A/S ADS	C	C	B	$33.23
VTRSViatris Inc. Common Stock	B	C	B	$16.34
ASNDAscendis Pharma A/S Ordinary Share	D	A	C	$247.91
JAZZJazz Pharmaceuticals, Inc.	B	C	B	$244.54
BBIOBridgeBio Pharma, Inc. Common Stock	F	A	B	$76.60
BMRNBioMarin Pharmaceuticals Inc	C	C	B	$64.67
MDGLMadrigal Pharmaceuticals, Inc. Common Stock	D	A	B	$533.76
CORTCorcept Therapeutics Inc.	F	C	B	$113.88
ELANElanco Animal Health Incorporated Common Stock	C	B	C	$24.11
ARWRArrowhead Research Corporation	D	A	B	$84.91
SMMTSummit Therapeutics Inc. Common Stock	F	—	D	$13.73
AXSMAxsome Therapeutics, Inc	D	B	C	$199.02
RDYDr. Reddy's Laboratories Limited American Depositary Shares	D	D	C	$12.18
IONSIonis Pharmaceuticals, Inc. Common Stock	D	D	C	$61.05
CYTKCytokinetics Inc.	F	D	C	$72.09
ABVXAbivax SA American Depositary Shares	—	—	C	$113.35
NUVLNuvalent, Inc. Class A Common Stock	—	—	B	$123.96
PRAXPraxis Precision Medicines, Inc. Common Stock	F	—	B	$344.75
PTGXProtagonist Therapeutics, Inc	F	B	B	$144.33
CRNXCrinetics Pharmaceuticals, Inc.	F	A	A	$84.84
TGTXTG Therapeutics, Inc.	D	B	B	$53.93
SYRESpyre Therapeutics, Inc. Common Stock	—	—	B	$90.36
ALKSAlkermes Inc. plc	D	C	B	$47.41
RYTMRhythm Pharmaceuticals, Inc. Common Stock	F	B	C	$107.17
ERASErasca, Inc. Common Stock	—	—	A	$18.03
TVTXTravere Therapeutics, Inc. Common Stock	F	B	A	$65.67
BLTEBelite Bio, Inc American Depositary Shares	—	—	C	$151.72

About Foghorn Therapeutics Inc. Common Stock

Foghorn Therapeutics discovers and develops medicines targeting dependencies in the chromatin regulatory system using its proprietary Gene Traffic Control platform. The company is advancing two lead candidates—FHD-286, a selective ATPase inhibitor, and FHD-609, a protein degrader—for the treatment of hematologic cancers and solid tumors.